gemcitabine has been researched along with 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashley, RA | 1 |
| Dorr, RT; Landowski, TH; Samulitis, BK | 1 |
| Boytim, ML; Cohen, SJ; Conkling, P; Davis, P; Dorr, RT; Hersh, EM; Modiano, MR; Patt, YZ; Zalupski, MM | 1 |
| Dorr, RT; Landowski, TH; Roman, NO; Samulitis, BK; Wisner, L | 1 |
| Cohen, SJ; Conkling, P; Hersh, E; Lee, FC; Ma, WW; Modiano, M; Nugent, F; Pascual, R; Wong, L; Zalupski, MM | 1 |
2 trial(s) available for gemcitabine and 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one
| Article | Year |
|---|---|
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Cystine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Half-Life; Hexanones; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sulfhydryl Compounds; Tomography, X-Ray Computed | 2010 |
A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Hexanones; Humans; Male; Middle Aged; Pancreatic Neoplasms; Progression-Free Survival | 2018 |
3 other study(ies) available for gemcitabine and 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one
| Article | Year |
|---|---|
Rob Ashley of AmpliMed discusses the discovery and development of Imexon. Interview by Steve Carney.
Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Deoxycytidine; Doxycycline; Drug Industry; Drug Synergism; Gemcitabine; Hexanones; Humans; Neoplasms; Tetracyclines | 2005 |
Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells.
Topics: Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Hexanones; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Protein Synthesis Inhibitors | 2009 |
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Hexanones; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Pancreatic Neoplasms; Ribonucleotide Reductases; Xenograft Model Antitumor Assays | 2011 |